

Christian Becker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3217270/publications.pdf>

Version: 2024-02-01

56
papers

3,620
citations

201674
27
h-index

161849
54
g-index

56
all docs

56
docs citations

56
times ranked

5715
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. <i>Journal of Experimental Medicine</i> , 2007, 204, 1303-1310.	8.5	524
2	Lysozyme M-Positive Monocytes Mediate Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. <i>Circulation</i> , 2011, 124, 1370-1381.	1.6	422
3	Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. <i>Nature Immunology</i> , 2018, 19, 1319-1329.	14.5	274
4	The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2016, 7, 123.	4.8	213
5	Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their energy and suppressive function. <i>Blood</i> , 2007, 110, 1550-1558.	1.4	181
6	Human CD25 ⁺ regulatory T cells: two subsets defined by the integrins $\alpha_4\beta_7$ or $\alpha_4\beta_1$ confer distinct suppressive properties upon CD4 ⁺ T helper cells. <i>European Journal of Immunology</i> , 2004, 34, 1303-1311.	2.9	165
7	Adoptive tumor therapy with T lymphocytes enriched through an IFN- γ capture assay. <i>Nature Medicine</i> , 2001, 7, 1159-1162.	30.7	154
8	Targeting of Antigens to Activated Dendritic Cells In vivo Cures Metastatic Melanoma in Mice. <i>Cancer Research</i> , 2005, 65, 7007-7012.	0.9	139
9	Angiotensin II-Induced Vascular Dysfunction Depends on Interferon- γ -Driven Immune Cell Recruitment and Mutual Activation of Monocytes and NK-Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1313-1319.	2.4	131
10	Polypeptoid-block-polypeptide Copolymers: Synthesis, Characterization, and Application of Amphiphilic Block Copolypept(o)ides in Drug Formulations and Miniemulsion Techniques. <i>Biomacromolecules</i> , 2014, 15, 548-557.	5.4	122
11	Inflammatory Monocytes Determine Endothelial Nitric-oxide Synthase Uncoupling and Nitro-oxidative Stress Induced by Angiotensin II. <i>Journal of Biological Chemistry</i> , 2014, 289, 27540-27550.	3.4	96
12	Interferon- γ Suppresses cAMP to Disarm Human Regulatory T Cells. <i>Cancer Research</i> , 2013, 73, 5647-5656.	0.9	87
13	miR-155 Inhibition Sensitizes CD4+ Th Cells for TREG Mediated Suppression. <i>PLoS ONE</i> , 2009, 4, e7158.	2.5	79
14	Cyclic AMP underpins suppression by regulatory T cells. <i>European Journal of Immunology</i> , 2012, 42, 1375-1384.	2.9	70
15	Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+CD25+ regulatory T cells. <i>Blood</i> , 2009, 114, 1263-1269.	1.4	67
16	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 538-564.	3.4	64
17	Innate Effector-Memory T-Cell Activation Regulates Post-Thrombotic Vein Wall Inflammation and Thrombus Resolution. <i>Circulation Research</i> , 2016, 119, 1286-1295.	4.5	61
18	Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells. <i>Blood</i> , 2013, 122, 1182-1191.	1.4	58

#	ARTICLE	IF	CITATIONS
19	Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. <i>International Journal of Cancer</i> , 2006, 118, 2617-2627.	5.1	57
20	CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. <i>Basic Research in Cardiology</i> , 2013, 108, 386.	5.9	55
21	Dendritic Cells: Sentinels of Immunity and Tolerance. <i>International Journal of Hematology</i> , 2005, 81, 197-203.	1.6	49
22	Increased regulatory Tâ€cell frequencies in patients with advanced melanoma correlate with a generally impaired Tâ€cell responsiveness and are restored after dendritic cellâ€based vaccination. <i>Experimental Dermatology</i> , 2010, 19, e213-21.	2.9	41
23	Efficient Gene Transfer into Primary Human CD8+T Lymphocytes by MuLV-10A1 Retrovirus Pseudotype. <i>Human Gene Therapy</i> , 2000, 11, 1005-1014.	2.7	40
24	Repression of Cyclic Adenosine Monophosphate Upregulation Disarms and Expands Human Regulatory T Cells. <i>Journal of Immunology</i> , 2012, 188, 1091-1097.	0.8	40
25	Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e77634.	2.5	40
26	CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice. <i>Cardiovascular Research</i> , 2018, 114, 312-323.	3.8	37
27	CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. <i>European Journal of Immunology</i> , 2007, 37, 1217-1223.	2.9	29
28	CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 521-528.e7.	2.9	28
29	Specialized regulatory T cells control venous blood clot resolution through SPARC. <i>Blood</i> , 2021, 137, 1517-1526.	1.4	27
30	Deep vein thrombus formation induced by flow reduction in mice is determined by venous side branches. <i>Clinical Hemorheology and Microcirculation</i> , 2014, 56, 145-152.	1.7	26
31	Regulatory T cells: present facts and future hopes. <i>Medical Microbiology and Immunology</i> , 2006, 195, 113-124.	4.8	23
32	Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy. <i>Nanomedicine</i> , 2016, 11, 2699-2709.	3.3	19
33	Translating Treg Therapy in Humanized Mice. <i>Frontiers in Immunology</i> , 2015, 6, 623.	4.8	17
34	<scp>GARP</scp> inhibits allergic airway inflammation in a humanized mouse model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1274-1283.	5.7	17
35	Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2019, 9, 7145.	3.3	17
36	Inflammatory Monocyte Counts Determine Venous Blood Clot Formation and Resolution. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 145-155.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. <i>European Journal of Immunology</i> , 1997, 27, 1657-1662.	2.9	16
38	MLV-10A1 retrovirus pseudotype efficiently transduces primary human CD4+ T lymphocytes. <i>Journal of Gene Medicine</i> , 2000, 2, 409-415.	2.8	16
39	Boosting regulatory T cell function by CD4 stimulation enters the clinic. <i>Frontiers in Immunology</i> , 2012, 3, 164.	4.8	15
40	Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. <i>Nature Communications</i> , 2021, 12, 5981.	12.8	13
41	Targeted Activation of T Cells with IL-2-Coupled Nanoparticles. <i>Cells</i> , 2020, 9, 2063.	4.1	12
42	Intervention of Inflammatory Monocyte Activity Limits Dermal Fibrosis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2144-2153.	0.7	11
43	Suppression of Tumour-Specific Cytotoxic T-Cell Responses Against the Syngeneic BALB/c Plasmacytoma ADJ-PC-5 by Tumour-Induced CD8 + Regulatory T Cells Via IFN- γ . <i>Scandinavian Journal of Immunology</i> , 1996, 43, 421-430.	0.7	9
44	Lymphokine profile and activation pattern of two unrelated antigen- or idiotypic-specific T suppressor cell clones. <i>European Journal of Immunology</i> , 1992, 22, 1961-1966.	2.9	8
45	Interaction of γ -N-(2-Hydroxypropyl)Methacrylamide Based Homo, Random and Block Copolymers with Primary Immune Cells. <i>Journal of Biomedical Nanotechnology</i> , 2014, 10, 81-91.	1.1	6
46	Generation of monoclonal antibodies against human regulatory T cells. <i>Journal of Immunological Methods</i> , 2010, 353, 62-70.	1.4	5
47	Interferon γ interferes with immunological tolerance. <i>Oncolimmunology</i> , 2013, 2, e27528.	4.6	5
48	Acute deep vein thrombosis suppresses peripheral T cell effector function. <i>British Journal of Haematology</i> , 2019, 184, 847-850.	2.5	5
49	CD8+ tumor-specific Tc cells primed in vivo or in vitro against the BALB/c plasmacytoma ADJ-PC-5 use the same TcR V α 3B2; families but display distinct TC1 or TC2 characteristics. <i>Immunobiology</i> , 1997, 197, 16-30.	1.9	3
50	Unexpected role of natural killer cell-derived interferon- γ as a driver of NETosis and DVT. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 400-402.	3.8	3
51	T Helper Target Cell DNA Fragmentation through a CD4-Positive T Suppressor Cell Clone Inducing Specific Unresponsiveness. <i>Cellular Immunology</i> , 1994, 153, 505-515.	3.0	2
52	Differential Activation of CD8+Tumor-Specific Tc1 and Tc2 Cells by an IL-10-Producing Murine Plasmacytoma. <i>Autoimmunity</i> , 1998, 6, 331-342.	0.6	2
53	CD8+ T cells armed with retrovirally transduced IFN- γ . <i>Journal of Molecular Medicine</i> , 2006, 85, 63-73.	3.9	2
54	Large scale preparation of human MHC class II+ integrin β 21+ Tregs. <i>Journal of Immunological Methods</i> , 2010, 360, 96-102.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Isolation and Expansion of Tumor-Specific CD4 ⁺ T-Cells by Means of Cytokine Secretion. , 2005, 109, 257-264.		0
56	Direct and indirect T _H 1 cell priming by dendritic cell vaccines. European Journal of Immunology, 1999, 29, 225-234.	2.9	0